• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝移植治疗肝细胞癌:结果与新型手术方法。

Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.

机构信息

University Health Network, Toronto General Hospital, Department of Surgery, University of Toronto, 585 University Avenue, 11-PMB-184, Toronto Ontario M5G2N2, Canada.

Barcelona Clinic Liver Cancer group, Liver Unit, Hospital Clinic, University of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Villaroel 170, Barcelona 08036, Spain.

出版信息

Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):203-217. doi: 10.1038/nrgastro.2016.193. Epub 2017 Jan 5.

DOI:10.1038/nrgastro.2016.193
PMID:28053342
Abstract

Liver transplantation for hepatocellular carcinoma (HCC) is the best treatment option for patients with early-stage tumours and accounts for ∼20-40% of all liver transplantations performed at most centres worldwide. The Milan criteria are the most common criteria to select patients with HCC for transplantation but they can be seen as too restrictive. Several proposals have been made for a moderate expansion of the criteria, which result in good outcomes but with an increase in the risk of tumour recurrence. In this Review, we provide a comprehensive overview of the outcomes after liver transplantation for HCC, focusing on tumour recurrence in terms of surveillance, prevention and treatment. Additionally, novel surgical techniques have been developed to increase the available pool of organs for liver transplantation (such as living donor liver transplantation, donation after circulatory death and split livers), but the effect of these techniques on patients with HCC is still under debate. Thus, we will describe these techniques and expose the benefits and disadvantages of each surgical approach. Finally, we will comment on the limitations of the current priority policies for liver transplantation and the need to further refine them to better serve the population.

摘要

肝移植是治疗早期肝癌(HCC)的最佳选择,约占全球大多数中心进行的所有肝移植的 20-40%。米兰标准是选择 HCC 患者进行移植的最常用标准,但它们可能被认为过于严格。已经提出了一些适度扩大标准的建议,这些建议可以带来良好的结果,但肿瘤复发的风险增加。在这篇综述中,我们全面概述了 HCC 肝移植后的结果,重点关注肿瘤复发的监测、预防和治疗。此外,还开发了新的手术技术来增加可用于肝移植的器官供应(如活体供肝移植、循环死亡后捐献和劈裂肝),但这些技术对 HCC 患者的影响仍存在争议。因此,我们将描述这些技术,并介绍每种手术方法的优缺点。最后,我们将评论当前肝移植优先政策的局限性以及需要进一步完善这些政策以更好地为人群服务的必要性。

相似文献

1
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.肝移植治疗肝细胞癌:结果与新型手术方法。
Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):203-217. doi: 10.1038/nrgastro.2016.193. Epub 2017 Jan 5.
2
Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.影响肝细胞癌肝移植生存因素的研究:来自布达佩斯的单中心经验
Transplant Proc. 2015 Sep;47(7):2201-6. doi: 10.1016/j.transproceed.2015.07.026.
3
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.肝癌肿瘤降期后行肝移植的研究(XXL):一项随机、对照、2b/3 期临床试验。
Lancet Oncol. 2020 Jul;21(7):947-956. doi: 10.1016/S1470-2045(20)30224-2.
4
Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.米兰标准以外的肝细胞癌的外科治疗。肝切除、挽救性移植和原位肝移植的结果。
Ann Surg Oncol. 2008 May;15(5):1383-91. doi: 10.1245/s10434-008-9851-z. Epub 2008 Mar 5.
5
Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.ABO 不相容成人活体肝移植治疗肝细胞癌患者的结局。
J Hepatol. 2018 Jun;68(6):1153-1162. doi: 10.1016/j.jhep.2018.02.002. Epub 2018 Feb 13.
6
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.验证 AFP 模型作为预测病毒肝炎相关性肝硬化患者 HCC 复发的指标,这些患者因 HCC 已接受肝移植。
J Hepatol. 2017 Mar;66(3):552-559. doi: 10.1016/j.jhep.2016.10.038. Epub 2016 Nov 27.
7
Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.供体肝移植后肝细胞肝癌患者的临床结局。
World J Gastroenterol. 2013 Aug 7;19(29):4737-44. doi: 10.3748/wjg.v19.i29.4737.
8
How far can we go with hepatocellular carcinoma in living donor liver transplantation?在活体肝移植中,我们能在多大程度上治疗肝细胞癌?
Curr Opin Organ Transplant. 2019 Oct;24(5):644-650. doi: 10.1097/MOT.0000000000000692.
9
Living donor liver transplantation or resection for Child-Pugh A hepatocellular carcinoma patients with multiple nodules meeting the Milan criteria.对于符合米兰标准的多发性结节Child-Pugh A级肝细胞癌患者,进行活体供肝肝移植或肝切除术。
Transpl Int. 2014 Jun;27(6):562-9. doi: 10.1111/tri.12297. Epub 2014 Apr 2.
10
Living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria: outcome of expanded criteria in tumor size.米兰标准以外的肝癌患者的活体肝移植:肿瘤大小扩展标准的结果。
BMC Surg. 2021 Nov 19;21(1):401. doi: 10.1186/s12893-021-01403-z.

引用本文的文献

1
Prognostic Significance of Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Liver Transplantation for Hepatocellular Carcinoma.血红蛋白、白蛋白、淋巴细胞和血小板(HALP)评分在肝细胞癌肝移植中的预后意义
Curr Oncol. 2025 Aug 16;32(8):464. doi: 10.3390/curroncol32080464.
2
Ginkgolic acid inhibits CD8 T cell activation and induces ferroptosis by lactate dehydrogenase A to exert immunosuppressive effect.银杏酸抑制CD8 T细胞活化,并通过乳酸脱氢酶A诱导铁死亡以发挥免疫抑制作用。
J Pharm Anal. 2025 Jul;15(7):101233. doi: 10.1016/j.jpha.2025.101233. Epub 2025 Feb 19.
3
Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors.

本文引用的文献

1
Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.肝细胞癌肝移植后的复发:故事的新寓意。
Ann Surg. 2017 Mar;265(3):557-564. doi: 10.1097/SLA.0000000000001966.
2
Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era.近期丙型肝炎感染供肝利用与废弃情况的变化
Am J Transplant. 2017 Feb;17(2):519-527. doi: 10.1111/ajt.13976. Epub 2016 Aug 24.
3
Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation: Impact of Treatment Modality and Recurrence Characteristics.
肝移植后肝细胞癌复发的管理:免疫检查点抑制剂的新作用
Discov Oncol. 2025 Jul 28;16(1):1431. doi: 10.1007/s12672-025-03226-3.
4
Curcumin as a therapeutic agent in liver cancer: a systematic review of preclinical models and mechanisms.姜黄素作为肝癌治疗药物:对临床前模型及机制的系统评价
Eur J Med Res. 2025 Jul 21;30(1):640. doi: 10.1186/s40001-025-02922-8.
5
A novel miRNA-based model for predicting the 3-year recurrence risk of hepatocellular carcinoma following liver transplantation.一种基于微小RNA的新型模型,用于预测肝移植后肝细胞癌的3年复发风险。
J Gastrointest Oncol. 2025 Jun 30;16(3):1208-1219. doi: 10.21037/jgo-2025-9. Epub 2025 Jun 27.
6
Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: Review and bibliometric.肝细胞癌患者肝移植选择标准的预后作用:综述与文献计量学分析
ILIVER. 2024 Feb 6;3(1):100077. doi: 10.1016/j.iliver.2024.100077. eCollection 2024 Mar.
7
CCL16 inhibits tumor proliferation and metastasis in HCC by impacting CK19 phenotype.CCL16 通过影响CK19表型抑制肝癌的肿瘤增殖和转移。
ILIVER. 2024 May 20;3(2):100096. doi: 10.1016/j.iliver.2024.100096. eCollection 2024 Jun.
8
Diagnostic performance comparisons of two commonly used multi-biomarker-based scores for detection of hepatocellular carcinoma in non-alcoholic fatty liver disease.两种常用的基于多种生物标志物的评分在非酒精性脂肪性肝病中检测肝细胞癌的诊断性能比较
ILIVER. 2024 May 21;3(2):100098. doi: 10.1016/j.iliver.2024.100098. eCollection 2024 Jun.
9
Liver transplantation for malignant liver tumors.恶性肝肿瘤的肝移植
ILIVER. 2022 Apr 18;1(1):3-11. doi: 10.1016/j.iliver.2022.04.002. eCollection 2022 Mar.
10
Risk factors associated with adverse cardiovascular events during orthotopic liver transplantation and the early post-transplant period.原位肝移植及移植后早期与不良心血管事件相关的危险因素。
Croat Med J. 2025 Jul 5;66(3):194-203.
预测肝移植后复发性肝细胞癌患者的死亡率:治疗方式和复发特征的影响
Ann Surg. 2017 Jul;266(1):118-125. doi: 10.1097/SLA.0000000000001894.
4
Defining Benchmarks for Major Liver Surgery: A multicenter Analysis of 5202 Living Liver Donors.定义大型肝外科手术的基准:5202 例活体肝移植供者的多中心分析。
Ann Surg. 2016 Sep;264(3):492-500. doi: 10.1097/SLA.0000000000001849.
5
A Novel Prognostic Index in Patients With Hepatocellular Cancer Waiting for Liver Transplantation: Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) Score.一种新型的肝癌患者肝移植等待期预后指标:时间-影像学-甲胎蛋白-炎症(TRAIN)评分。
Ann Surg. 2016 Nov;264(5):787-796. doi: 10.1097/SLA.0000000000001881.
6
Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.肝细胞癌与直接作用抗病毒治疗:变革后的争议
J Hepatol. 2016 Oct;65(4):663-665. doi: 10.1016/j.jhep.2016.07.004. Epub 2016 Jul 12.
7
Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.丙型肝炎相关肝细胞癌肝移植术后的直接抗病毒治疗与肿瘤复发
J Hepatol. 2016 Oct;65(4):859-860. doi: 10.1016/j.jhep.2016.06.023. Epub 2016 Jul 5.
8
Technical Skills Required in Split Liver Transplantation.活体肝移植所需的技术技能。
Ann Transplant. 2016 Jul 1;21:408-15. doi: 10.12659/aot.896351.
9
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
10
Normothermic ex vivo liver perfusion using steen solution as perfusate for human liver transplantation: First North American results.使用Steen溶液作为灌注液进行常温离体肝灌注用于人类肝移植:北美首例结果。
Liver Transpl. 2016 Nov;22(11):1501-1508. doi: 10.1002/lt.24499.